SRSF2 mutations in epithelial ovarian cancer

 

Authors

  • Milena Sabrina Nicoloso Equally contributed
  • Monica Schiappacassi Equally contributed
  • Alessandra Dall’Acqua Division of Molecular Oncology, CRO Aviano, IRCCS, National Cancer Institute, Aviano, Italy.
  • Sara D’Andrea Division of Molecular Oncology, CRO Aviano, IRCCS, National Cancer Institute, Aviano, Italy.
  • Sara Benevol Division of Molecular Oncology, CRO Aviano, IRCCS, National Cancer Institute, Aviano, Italy.
  • Roberto Sorio Medical Oncology B, CRO Aviano, IRCCS, National Cancer Institute, Aviano, Italy.
  • Vincenzo Canzonieri Pathology, CRO Aviano, IRCCS, National Cancer Institute, Aviano, Italy.
  • Giorgio Giorda Gynecology-Oncology, CRO Aviano, IRCCS, National Cancer Institute, Aviano, Italy.
  • Gustavo Baldassarre Division of Molecular Oncology, CRO Aviano, IRCCS, National Cancer Institute, Aviano, Italy.

DOI:

https://doi.org/10.19156/cbn.2017.0056

Keywords:

epithelial ovarian cancer, platinum treatment, alternative splicing, SRSF2

Abstract

Resistance to platinum chemotherapy regimens represents a major obstacle in the successful treatment of epithelial ovarian cancer (EOC) patients. Among the molecular mechanism responsible for resistance to platinum, alternative splicing, which is induced upon platinum treatment, can control apoptosis by regulating the expression of apoptotic protein variants with opposite functions. Alterations in alternative splicing are found in tumors and can hinder apoptotic response. In the present study we sequenced SRSF2, a splicing factor that regulates Caspase-8 and Caspase-9 variants, in search of mutations that could possibly explain alternative mechanisms of platinum resistant in EOC.

Downloads

Published

2017-12-15

How to Cite

1.
Nicoloso MS, Schiappacassi M, Dall’Acqua A, D’Andrea S, Benevol S, Sorio R, Canzonieri V, Giorda G, Baldassarre G. SRSF2 mutations in epithelial ovarian cancer:  . CBN [Internet]. 2017 Dec. 15 [cited 2024 Nov. 21];5(3):25-9. Available from: https://journals.aboutscience.eu/index.php/cancerbreakingnews/article/view/192

Issue

Vol. 5 No. 3 (2017): December 2017

Section

Clinical original article

License

Articles published in Cancer Breaking News are distributed under the CC Attribution-NonCommercial-NoDerivatives 4.0 license, which allows third parties to copy and redistribute the material providing appropriate credit and a link to the license but does not allow to use the material for commercial purposes and to use the material if it has been remixed, transformed or built upon.